Association of Tissue mRNA and Serum Antigen Levels of Members of the Urokinase-Type Plasminogen Activator System with Clinical and Prognostic Parameters in Prostate Cancer

Table 2

Univariate and multivariate Cox’s regression analysis of the association of uPA, PAI-1, and uPAR serum levels in PCa patients with OS (𝑛=81).

Parameters	Number of cases	Univariate analysis	𝑃	Multivariate analysis^1	𝑃	Multivariate analysis^2	𝑃
		HR (95% CI)		HR (95% CI)		HR (95% CI)
	81
uPA serum*
Low/intermediate	54	1		1		1.15 (0.12–6.42)	0.890
High	27	3.34 (0.73–15.20)	0.119	2.49 (0.51–12.25)	0.261	1
PAI-1 serum*
Low/intermediate	54	1		1		1
High	27	2.53 (0.56–11.30)	0.226	4.94 (0.85–28.76)	0.076	3.06 (0.53–17.55)	0.209
uPAR serum*
Low/intermediate	54	1		1		1
High	27	5.48 (1.06–28.29)	0.042	7.12 (1.25–40.69)	0.027	5.64 (0.79–40.35)	0.085

HR: hazard ratio (95% confidence interval) of the univariate and multivariate Cox’s regression hazard analysis.
Multivariate analysis was adjusted to relevant clinicopathological parameters: ¹age, lymph node status, tumor stage, and Gleason score.
²Age, lymph node status, tumor stage, and Gleason score and with all three uPA components covariates added at once.
*Serum antigen levels of uPA system components (ng/mL) were divided into low, intermediate, and high levels by the 33% percentiles (tertiles); low/intermediate: 0–66% percentile; high: >66–100% percentile.